ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2009;87:1914-1917. doi:10.1016/j.athoracsur.2009.01.054
© 2009 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Sven Martens
Anton Moritz
Mirko Doss
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Martens, S.
Right arrow Articles by Doss, M.
PubMed
Right arrow Articles by Martens, S.
Right arrow Articles by Doss, M.
Related Collections
Right arrow Valve disease
Right arrowRelated Article

New Technology

Sutureless Aortic Valve Replacement With the 3f Enable Aortic Bioprosthesis

Sven Martens, MD*, Anja Ploss, MD, Sami Sirat, MD, Alexandra Miskovic, MD, Anton Moritz, MD, Mirko Doss, MD

Department of Thoracic and Cardiovascular Surgery, JW Goethe University Hospital, Frankfurt, Germany

Accepted for publication January 21, 2009.

* Address correspondence to Dr Martens, Department of Thoracic and Cardiovascular Surgery, JW Goethe University Hospital, Thoedor Stern Kai 7, Frankfurt, D-60590, Germany (Email: martens.herz{at}gmx.de).

Purpose: Important comorbid conditions in elderly patients referred for aortic valve replacement require alternative treatment options with possible reduction of the extracorporeal circuit time and reliable hemodynamic features. We report on clinical experiences with the sutureless, nitinol-stented 3f Enable (ATS Medical, Minneapolis, MN) aortic valve prosthesis in 32 patients.

Description: The procedure was performed using cardiopulmonary bypass with cardioplegic arrest. After resection of the stenotic aortic valve and debridement of the annulus, the valve was inserted and released. Mean age was 78 ± 3; mean logistic Euroscore was 13.7. Concomitant procedures were mitral valve and tricuspid valve repair (n = 1), coronary artery bypass graft (n = 9), and subvalvular myectomy (n = 3).

Evaluation: Implantation of the valve required 9 ± 5 minutes. Cardiopulmonary bypass and aortic cross-clamp time were 87 ± 16 and 55 ± 11 minutes for stand-alone procedures. Combined procedures required 126 ± 42 and 84 ± 28 minutes, respectively. Two patients were abandoned intraoperatively and converted to standard procedures due to misalignment of the valve. In the other 30 patients, no paravalvular leakage was detected. The transvalvular gradient at discharge was 9 ± 6 mm Hg (mean) and 18 ± 9 mm Hg (peak). Six months after surgery, gradients were 10 ± 4 mm Hg (mean) and 18 ± 6 mm Hg (peak).

Conclusions: Sutureless valve implantation is feasible and safe with the 3f Enable (ATS Medical) bioprosthesis. Reduction of cardiopulmonary bypass and aortic cross-clamp time seems to be possible with increasing experience. Hemodynamic data are promising with low gradients at discharge and after 6 months.


Related Article

Invited Commentary
George Magovern, Jr
Ann. Thorac. Surg. 2009 87: 1917-1918. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
G. Magovern Jr
Invited Commentary.
Ann. Thorac. Surg., June 1, 2009; 87(6): 1917 - 1918.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The Society of Thoracic Surgeons.